LW-02
immunicom
['breast', 'immunic']
#immunicom clinical trial data at #asco22 show #immunopheresis #lw02 column is safe and effectively depletes soluble #tnf receptors in patients with advanced triple negative #breastcancer 
Follow top-line development in the oncology commercial domain. Gain entry to KOL discussions, including both medical professionals and business leaders.